Intra-Cellular Therapies Price to Free Cash Flow Ratio 2013-2022 | ITCI

Historical price to free cash flow ratio values for Intra-Cellular Therapies (ITCI) since 2013. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Intra-Cellular Therapies Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-08-05 59.99 0.00
2022-03-31 61.19 $-3.51 0.00
2021-12-31 52.34 $-3.20 0.00
2021-09-30 37.28 $-3.24 0.00
2021-06-30 40.82 $-3.11 0.00
2021-03-31 33.93 $-3.08 0.00
2020-12-31 31.80 $-3.27 0.00
2020-09-30 25.66 $-2.95 0.00
2020-06-30 25.67 $-2.65 0.00
2020-03-31 15.37 $-2.47 0.00
2019-12-31 34.31 $-2.33 0.00
2019-09-30 7.47 $-2.24 0.00
2019-06-30 12.98 $-2.22 0.00
2019-03-31 12.18 $-2.32 0.00
2018-12-31 11.39 $-2.17 0.00
2018-09-30 21.70 $-2.10 0.00
2018-06-30 17.67 $-1.92 0.00
2018-03-31 21.05 $-1.88 0.00
2017-12-31 14.48 $-1.76 0.00
2017-09-30 15.78 $-1.95 0.00
2017-06-30 12.42 $-2.30 0.00
2017-03-31 16.25 $-2.04 0.00
2016-12-31 15.09 $-2.11 0.00
2016-09-30 15.24 $-2.39 0.00
2016-06-30 38.82 $-3.10 0.00
2016-03-31 27.80 $-3.31 0.00
2015-12-31 53.79 $-3.09 0.00
2015-09-30 40.04 $-2.31 0.00
2015-03-31 23.88 $-1.06 0.00
2014-12-31 17.65 $-0.80 0.00
2014-09-30 13.71 $-1.92 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.659B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.995B 9.34
GSK (GSK) United Kingdom $82.506B 9.91
Bio-Rad Laboratories (BIO.B) United States $16.008B 35.37
QIAGEN (QGEN) Netherlands $11.286B 18.90
Biohaven Pharmaceutical Holding (BHVN) United States $10.366B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.454B 0.00
Arcus Biosciences (RCUS) United States $1.972B 38.49
Emergent Biosolutions (EBS) United States $1.578B 9.15
Myovant Sciences (MYOV) United Kingdom $1.450B 0.00
Zymeworks (ZYME) Canada $0.376B 0.00
Enzo Biochem (ENZ) United States $0.123B 0.00
Gelesis Holdings (GLS) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
Ambrx Biopharma (AMAM) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00